Company / FCF Margin
KalVista Pharmaceuticals, Inc. FCF Margin History
FY2018-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-238.4%
FY2020
5-year range
-
FY2018-FY2020
Trend
+84.9%
vs FY2019
Sector context
#102 of 133
Health Care
What the data says
KalVista Pharmaceuticals, Inc.'s fcf margin of -238.4% is lower than 77% of companies in the Health Care sector (FY2020). Improved from -617.3% to -238.4% over the past 2 years.
Based on SEC 10-K filings.
-238.4% in FY2020.
Improved from -617.3% to -238.4% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 133This company -238.4% Sector average -632.8%
▼
+62.3% above sector average
Key checks
Key Insights
- In FY2020, fcf margin increased 84.9% year-over-year.
- Currently 394.4pp above the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | -238.4% | +84.9% |
| FY2019 | -1582.2% | -156.3% |
| FY2018 | -617.3% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2020 · SEC 10-K · Updated Jun 30, 2026